Feature Article | Why Leen Kawas Believes the Future of Drug Development Starts With Patients

Nine out of ten experimental drugs that enter human trials never make it to market, and Leen Kawas says the top reason is one the industry treats as unavoidable: nobody asked patients what mattered before the science was already locked in. This piece covers her patient-first investment thesis at Propel Bio Partners, with real examples from her own portfolio of what building backward from patient need actually looks like.

Read the Full Article Here